搜索
 > 【CD38】重组蛋白信息

CD38信息

英文名称:Lymphocyte differentiation antigen CD38
中文名称:淋巴细胞分化抗原CD38
靶点别称:2'-phospho-ADP-ribosyl cyclase,T10,CD38,2'-phospho-cyclic-ADP-ribose transferase,CD_antigen=CD38,2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase,ADPRC 1,Cyclic ADP-ribose hydrolase 1,ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase
上市药物数量:1
临床药物数量:10
最高研发阶段:批准上市

CD38产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
CD8-H5224
Human
Human CD38 Protein, His Tag
CD8-H82E7
Human
Biotinylated Human CD38 Protein, Avitag,His Tag
CD8-H5255
Human
Human CD38, Fc Tag
CD8-H5253
Human
Human CD38 Protein, mouse IgG2a Fc Tag, low endotoxin
CD8-H5252
Human
Human CD38 Protein, Llama IgG2b Fc Tag, low endotoxin
CD8-C5223
Cynomolgus
Cynomolgus CD38 Protein, His Tag
CD8-M5223
Mouse
Mouse CD38 Protein, His Tag

CD38 分子别名

CD38,T10,cADPr hydrolase 1

CD38 分子背景

CD antigen CD38 is also known as ADP-ribosyl cyclase 1, which belongs to the ADP-ribosyl cyclase family. CD38 is expressed at high levels in pancreas, liver, kidney, brain, testis, ovary, placenta, malignant lymphoma and neuroblastoma. CD38 is a multifunctional ectoenzyme that catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD+ to ADP-ribose. These reaction products are essential for the regulation of intracellular Ca2+. The loss of CD38 function is associated with impaired immune responses, metabolic disturbances, and behavioral modifications. The CD38 protein is a marker of cell activation. It has been connected to HIV infection, leukemias, myelomas, solid tumors, type II diabetes mellitus and bone metabolism. CD38 has been used as a prognostic marker in leukemia.

CD38 参考文献

CD38上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Daratumumab 3003-005; HuMax-CD38; JNJ-54767414; Dara-SC ,HuMaxCD38 批准上市 杨森 DARZALEX fda 多发性骨髓瘤 JANSSEN BIOTECH 2015-11-16 多发性骨髓瘤 详情

CD38临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
GBR-1342 GBR-1342 临床一期 Glenmark Pharma 多发性骨髓瘤
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) 临床一期 武汉协和医院, Shengyan Pharmaceutical Technology 多发性骨髓瘤
TAK-079 TAK-079,TAK079 临床二期 武田 多发性骨髓瘤 详情
AMG-424 AMG-424 临床一期 Xencor, 安进 多发性骨髓瘤 详情
Isatuximab SAR-650984,SAR650984 BLA 申请 ImmunoGen, 赛诺菲 多发性骨髓瘤 详情
TAK-573 TAK-573; TEV-48573 临床二期 武田 多发性骨髓瘤 详情
TAK-169 TAK-169 临床申请 Molecular Templates, 武田 多发性骨髓瘤
FT-500 FT-500; FT-516; FT-538; FT-596 临床一期 Fate therapeutics, University of Minnesota 实体瘤 详情
Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) 临床一期 Sorrento Therapeutics, Celularity 多发性骨髓瘤
MOR-202 MOR-202; MOR-03087; TJ-202 临床三期 MorphoSys, I-MAB Biopharma 多发性骨髓瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定